Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy

Domenico Cante; Maria Rosa La Porta; Pierfrancesco Franco; Piera Sciacero; Giuseppe Franco Girelli; Annamaria Marra; Gianmauro Numico; Nerina Denaro; Elvio Grazioso Russi; Umberto Ricardi

doi:10.1159/000355579

Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy

Domenico Cante
, Maria Rosa La Porta
, Pierfrancesco Franco
, Piera Sciacero
, Giuseppe Franco Girelli
, Annamaria Marra
, Gianmauro Numico
, Nerina Denaro
, Elvio Grazioso Russi
, Umberto Ricardi

Research output: Contribution to journal › Review article › peer-review

Abstract

It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.

Original language	English
Pages (from-to)	257-261
Number of pages	5
Journal	Oncology
Volume	85
Issue number	5
DOIs	https://doi.org/10.1159/000355579
Publication status	Published - Nov 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cetuximab
Dermatitis
Epidermal growth factor receptor
Head and neck cancer
Radiation-induced toxicity

Access to Document

10.1159/000355579

Cite this

@article{fbdb9bb04f4748c1a735f2d58000d7f4,

title = "Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy",

abstract = "It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.",

keywords = "Cetuximab, Dermatitis, Epidermal growth factor receptor, Head and neck cancer, Radiation-induced toxicity",

author = "Domenico Cante and \{La Porta\}, \{Maria Rosa\} and Pierfrancesco Franco and Piera Sciacero and Girelli, \{Giuseppe Franco\} and Annamaria Marra and Gianmauro Numico and Nerina Denaro and Russi, \{Elvio Grazioso\} and Umberto Ricardi",

year = "2013",

month = nov,

doi = "10.1159/000355579",

language = "English",

volume = "85",

pages = "257--261",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy

AU - Cante, Domenico

AU - La Porta, Maria Rosa

AU - Franco, Pierfrancesco

AU - Sciacero, Piera

AU - Girelli, Giuseppe Franco

AU - Marra, Annamaria

AU - Numico, Gianmauro

AU - Denaro, Nerina

AU - Russi, Elvio Grazioso

AU - Ricardi, Umberto

PY - 2013/11

Y1 - 2013/11

N2 - It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.

AB - It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.

KW - Cetuximab

KW - Dermatitis

KW - Epidermal growth factor receptor

KW - Head and neck cancer

KW - Radiation-induced toxicity

U2 - 10.1159/000355579

DO - 10.1159/000355579

M3 - Review article

SN - 0030-2414

VL - 85

SP - 257

EP - 261

JO - Oncology

JF - Oncology

IS - 5

ER -

Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this